Share This Page
Suppliers and packagers for TERLIVAZ
✉ Email this page to a colleague
TERLIVAZ
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Ireland | TERLIVAZ | terlipressin acetate | POWDER;INTRAVENOUS | 022231 | NDA | Mallinckrodt Hospital Products Inc. | 43825-200-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (43825-200-01) / 5 mL in 1 VIAL, SINGLE-DOSE | 2022-09-14 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for TERLIVAZ
Terlivaz (terlipressin) drug suppliers: who manufactures bulk drug, finished dosage, and key contract manufacturers
Executive summary: Sufficient, citable information on the exact suppliers (API manufacturers, finished-dose manufacturers, and named contract manufacturing organizations) for TERLIVAZ is not available in the provided context to produce a complete and accurate supplier map.
What companies supply TERLIVAZ and its active ingredient terlipressin?
Answer: Not available from the provided information.
API supply chain: who makes terlipressin
Answer: Not available from the provided information.
Common supplier categories for terlipressin
- API manufacturer (bulk terlipressin acetate/active salt)
- Intermediate supplier for peptide/solution-form synthesis steps
- Finished-dose manufacturer (ampoule/vial filling and packaging)
- Contract fill-finish vendor (if applicable)
Finished-dose supply chain: who makes TERLIVAZ
Answer: Not available from the provided information.
Packaging form that affects supplier set
- Injection in vial or ampoule
- Unit-dose packaging for hospital distribution
- Label/secondary packaging requirements per market
How many suppliers are in the TERLIVAZ terlipressin value chain?
Answer: Not available from the provided information.
Supplier count drivers
- Single-source vs dual-source API
- Separate fill-finish vs integrated manufacturer
- Regionalization for distribution
Which contract manufacturers (CMOs) fill-finish TERLIVAZ?
Answer: Not available from the provided information.
Fill-finish scope that typically changes the CMO list
- Aseptic vial/ampoule fill
- Sterilization method (for relevance to manufacturer capability)
- Labeling and bundling for specific jurisdictions
What is the Orange Book status of TERLIVAZ (terlipressin) and how does it list suppliers?
Answer: Not available from the provided information.
How Orange Book listings link to suppliers
- Listed drug name
- Applicant/holder
- Labeler and manufacturer on product listings
- Patent and exclusivity ties that can indirectly reveal manufacturing partners
Does TERLIVAZ have pending Paragraph IV challenges that identify alternative suppliers?
Answer: Not available from the provided information.
Why litigation data can surface supply-chain substitutes
- “Reference listed drug” challenges can name applicants
- Settlements can disclose launch partners
- Discovery can surface manufacturing relationships
What patents protect TERLIVAZ and do they affect supplier qualification?
Answer: Not available from the provided information.
Typical supplier-impacting patent categories
- Formulation or concentration-specific patents
- Device/container compatibility patents
- Method-of-manufacture patents for sterility/assay control
- Process patents for the peptide synthesis steps
When does TERLIVAZ lose exclusivity, and which suppliers can enter after that?
Answer: Not available from the provided information.
Exclusivity timeline elements that determine supplier re-entry risk
- Regulatory exclusivity end date (where applicable)
- Patent expiry schedule
- Hatch-Waxman-type barriers (where applicable)
What generic or biosimilar risks exist for terlipressin products like TERLIVAZ?
Answer: Not available from the provided information.
Risk pathways that typically reveal alternative manufacturers
- Generic sponsor/ANDA holder
- Manufacturing site statements in regulatory filings
- Launch labeling and distribution agreements
Supplier mapping by geography: who supplies TERLIVAZ in each market?
Answer: Not available from the provided information.
Why geography changes suppliers
- Local MAH and distribution agreements
- Local manufacturing requirements
- Tender-driven sourcing for hospital systems
Key Takeaways
- No supplier list for TERLIVAZ (API and finished-dose manufacturers, including CMOs) can be produced from the provided input.
- No regulatory, exclusivity, litigation, or patent-linked supplier-identification can be constructed without underlying TERLIVAZ-specific source data.
FAQs
-
How can I identify the API manufacturer for TERLIVAZ?
Not available from the provided information. -
Does TERLIVAZ list a specific fill-finish CMO on regulatory product documents?
Not available from the provided information. -
Where do TERLIVAZ labelers and manufacturers appear in public regulatory databases?
Not available from the provided information. -
Do terlipressin generic applicants typically source from the same API suppliers as the brand?
Not available from the provided information. -
What evidence usually confirms the real-world TERLIVAZ manufacturing sites?
Not available from the provided information.
References
- (No sources were provided in the prompt.)
More… ↓
